Evofem Biosciences Inc (EVFM)
0.0141
0.00 (0.00%)
USD |
OTCM |
May 31, 16:00
Evofem Biosciences Debt to Equity Ratio: -0.5993 for March 31, 2024
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| March 31, 2024 | -0.5993 |
| December 31, 2023 | -0.6505 |
| September 30, 2023 | -0.7529 |
| June 30, 2023 | -0.7725 |
| March 31, 2023 | -0.8979 |
| December 31, 2022 | -0.9148 |
| September 30, 2022 | -0.9934 |
| June 30, 2022 | -0.5533 |
| Date | Value |
|---|---|
| March 31, 2022 | -0.8906 |
| December 31, 2021 | -1.094 |
| September 30, 2021 | -1.622 |
| June 30, 2021 | 7.865 |
| March 31, 2021 | -5.786 |
| December 31, 2020 | 57.62 |
| September 30, 2020 | 1.195 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
-5.786
Minimum
Mar 2021
57.62
Maximum
Dec 2020
3.410
Average
-0.7725
Median
Jun 2023
Debt to Equity Ratio Benchmarks
| Aditxt Inc | 0.6337 |
| NovaBay Pharmaceuticals Inc | 6.294 |
| Palatin Technologies Inc | -- |
| iBio Inc | -- |
| Theriva Biologics Inc | -- |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 8.217M |
| Total Liabilities (Quarterly) | 78.88M |
| Shareholders Equity (Quarterly) | -70.67M |
| Current Ratio | 0.0933 |
| Net Debt Paydown Yield | 397.5% |